Immuno-Oncology Drug Development: Challenges & Next Steps

PharmaTalk Radio's Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD,National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what's currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they also address: Ipilumumab/Nivo/Pembro challengesWhat can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?Challenges with the following modalities: Checkpoints, Oncolytic Virus', Adoptive T-Cells, Cancer VaccinesBlinitumumabThe more interesting agents in late stage development now in immunotherapy and its promiseImmune related adverse eventsAdoptive cellular therapies, what is the most promising?Will IO become backbone therapies for cancer?What's the next set of assets that are going to come out?Promises in combination therapies?What can we expect next? Guests: James Gulley, MD, PhD Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute Axel Hoos, MD, PhD, VP, Oncology R&D,GlaxoSmithKline The Immuno-Oncology360° conference is scheduled for February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.